Mucosal adjuvants
-
1
Medical Faculty and Institute of Basic and Preclinical Science “Victoria de Girón” and Latinoamerican School of Medicine, Havana medical science university, Department of Immunology, Cuba
-
2
Facultad de Ciencias Bioquímicas y Farmacéuticas de la Universidad Nacional de Rosario Argentina, Department of Microbiology, Argentina
-
3
Finlay Institute, Cuba
-
4
Medical Faculty and Institute of Basic and Preclinical Science “Victoria de Girón”, Cuba
-
5
Universidade Estadual Paulista (UNESP), PVE-CAPES Laboratório de Imunología Clínica.Faculdade de Ciências Farmacêuticas, Brazil
Background. Most vaccinologists have looking for specific antigens and the regulators have been pushing them to purified products eliminating the immunopotentiators agents coming from self-adjuvants. Nevertheless, adjuvants are determinant vaccine component, and undoubtedly the future of vaccine formulations; particularly for mucosal applications. Mucosa is challenged by the huge majority of infectious including commensal which do not produce disease but inducing immune response. In addition, mucosa is the only route capable to protect them self and to induce systemic immune response as parenteral route did. Nevertheless, few mucosal vaccines exist mainly due to the insufficient cognizance of mucosal immune functions and the absence of mucosal adjuvants.
Aim. To update adjuvant Finlay strategy and to show promising results combining mucosal and parenteral simultaneously priming.
Results. Adjuvant Finlay (AF), specifically the AFPL® and the AFCo were design for parenteral and mucosal application, respectively. AFPL®1 is derived from Neisseria meningitidis serogroup B proteoliposome (PL) and adsorbed onto Al(OH)3 in order to increase stability and safety. AFPL1 has been widely used in humans in a prophylactic meningococcal vaccine as an essential adjuvant. A comparable PL has been used in the 4CMenB Novartis vaccine. AFPL®1 has been also evaluated as an adjuvant for a therapeutic/prophylactic allergen vaccine shifting the allergen-specific Th2 pattern to Th1/Tr1 in mice and the Phase I clinical trial was recently concluded. AFPL®1 was used at preclinical stage with several other antigens. AFCo1, a cochleate structure derived from AFPL®1, is a mucosal adjuvant. AFCo3 non-derived from AFPL®1, has been tested as immunopotentiator in fish decreasing their mortality. As mucosal route required more doses than parenteral one two simultaneous primes by parenteral and mucosal routes were performed and surprising this strategy overcome the three doses required, inducing systemic and also mucosal immune response. Lastly, as covalent conjugation is the hallmark of thymus-independence bacterial polysaccharides vaccines we explored the coadministration of AFCo1 with plain polysaccharide and this combination overcome the thymus-independence inducing a Th1 polarization and memory immune response in mice.
Conclusion. AF are very promising adjuvants for unsolved-vaccine diseases including mucosal approaches and therapeutic vaccines.
Keywords:
Adjuvants, Immunologic,
Mucosa,
Vaccines,
Immune responses,
Vaccine formulations
Conference:
IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología, Medellin, Colombia, 13 Oct - 16 Oct, 2015.
Presentation Type:
Oral Presentation
Topic:
Mucosal Immunity and the microbiome
Citation:
Pérez
O,
Grau
RR,
González
E,
Tub-Chafer
F,
Ramos Pupo
R,
Reyes
LM,
Vega
IG,
Romeu
B,
Lastre
M and
Batista Duharte
A
(2015). Mucosal adjuvants.
Front. Immunol.
Conference Abstract:
IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología.
doi: 10.3389/conf.fimmu.2015.05.00196
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
14 May 2015;
Published Online:
14 Sep 2015.
*
Correspondence:
Prof. Oliver Pérez, Medical Faculty and Institute of Basic and Preclinical Science “Victoria de Girón” and Latinoamerican School of Medicine, Havana medical science university, Department of Immunology, Havana, Cuba, oliverperez@giron.sld.cu